TDMS Study 96021-01 Pathology Tables
NTP Experiment-Test: 96021-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TOXIC EQUIVALENCY FACTOR EVALUATION (PCB 153) Date: 12/15/03
Route: GAVAGE Time: 11:03:02
FINAL#4 RATS
Facility: Battelle Columbus Laboratory
Chemical CAS #: 35065-27-1
Lock Date: 01/16/02
Cage Range: All
Reasons For Removal: 25018 Dosing Accident 25019 Moribund Sacrifice
25020 Natural Death 25021 Terminal Sacrifice
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 96021-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TOXIC EQUIVALENCY FACTOR EVALUATION (PCB 153) Date: 12/15/03
Route: GAVAGE Time: 11:03:02
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 UG/KG 10 UG/KG 100 300 1000 3000
UG/KG UG/KG UG/KG UG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 98 86 98 98 98 80
Early Deaths
Natural Death 11 15 8 9 15 11
Moribund Sacrifice 18 23 17 22 18 19
Dosing Accident 1
Survivors
Terminal Sacrifice 24 16 28 20 20 21
Natural Death 1
Animals Examined Microscopically 53 54 53 53 53 51
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Colon (53) (54) (53) (53) (53) (50)
Intestine Large, Rectum (53) (54) (53) (53) (53) (50)
Intestine Large, Cecum (53) (54) (53) (53) (53) (50)
Leiomyoma 1 (2%)
Intestine Small, Duodenum (53) (54) (53) (53) (53) (51)
Intestine Small, Jejunum (53) (54) (53) (53) (53) (50)
Liver (53) (54) (53) (53) (53) (51)
Carcinoma, Metastatic, Uterus 1 (2%)
Cholangioma 2 (4%)
Hepatocellular Adenoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Mesentery (1) (1)
Carcinoma, Metastatic, Uterus 1 (100%)
Oral Mucosa (21) (12) (16) (12) (16) (25)
Gingival, Squamous Cell Carcinoma 2 (17%) 1 (8%) 1 (4%)
Pancreas (53) (54) (53) (53) (53) (51)
Salivary Glands (51) (52) (53) (52) (53) (51)
Stomach, Forestomach (53) (54) (53) (53) (53) (51)
Histiocytic Sarcoma 1 (2%)
Stomach, Glandular (53) (54) (53) (53) (53) (51)
Histiocytic Sarcoma 1 (2%)
Tooth (34) (13) (19) (22) (23) (35)
Peridontal Tissue, Neurofibrosarcoma 1 (3%)
____________________________________________________________________________________________________________________________________
Page 2
NTP Experiment-Test: 96021-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TOXIC EQUIVALENCY FACTOR EVALUATION (PCB 153) Date: 12/15/03
Route: GAVAGE Time: 11:03:02
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 UG/KG 10 UG/KG 100 300 1000 3000
UG/KG UG/KG UG/KG UG/KG
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Blood Vessel (52) (54) (53) (53) (53) (51)
Aorta, Hemangiosarcoma, Metastatic, Heart 1 (2%)
Heart (52) (54) (53) (53) (53) (51)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Schwannoma Malignant 1 (2%) 1 (2%) 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (53) (54) (53) (53) (53) (51)
Adenoma 1 (2%)
Adrenal Medulla (53) (54) (53) (53) (53) (51)
Pheochromocytoma Malignant 1 (2%) 1 (2%)
Pheochromocytoma Benign 2 (4%) 1 (2%) 4 (8%) 4 (8%) 2 (4%) 2 (4%)
Bilateral, Pheochromocytoma Benign 1 (2%)
Islets, Pancreatic (53) (54) (53) (53) (53) (51)
Adenoma 1 (2%)
Carcinoma 1 (2%)
Parathyroid Gland (49) (46) (50) (47) (46) (48)
Adenoma 2 (4%)
Pituitary Gland (53) (54) (53) (53) (53) (50)
Carcinoma, Metastatic, Oral Mucosa 1 (2%)
Neurofibrosarcoma, Metastatic, Tooth 1 (2%)
Pars Distalis, Adenoma 18 (34%) 19 (35%) 19 (36%) 19 (36%) 24 (45%) 11 (22%)
Pars Distalis, Carcinoma 1 (2%)
Thyroid Gland (51) (52) (53) (53) (53) (51)
Bilateral, C-Cell, Adenoma 2 (4%) 4 (8%) 5 (9%)
C-Cell, Adenoma 14 (27%) 9 (17%) 17 (32%) 11 (21%) 17 (32%) 6 (12%)
C-Cell, Adenoma, Multiple 1 (2%) 1 (2%)
C-Cell, Carcinoma 2 (4%) 2 (4%) 1 (2%) 1 (2%) 2 (4%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
Page 3
NTP Experiment-Test: 96021-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TOXIC EQUIVALENCY FACTOR EVALUATION (PCB 153) Date: 12/15/03
Route: GAVAGE Time: 11:03:02
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 UG/KG 10 UG/KG 100 300 1000 3000
UG/KG UG/KG UG/KG UG/KG
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (53) (51) (52) (53) (51) (50)
Carcinoma 1 (2%)
Carcinoma, Metastatic, Mammary Gland 1 (2%)
Ovary (53) (53) (53) (53) (53) (50)
Cystadenoma 1 (2%)
Granulosa Cell Tumor Malignant 1 (2%)
Granulosa Cell Tumor Benign 1 (2%)
Granulosa-Theca Tumor Benign 1 (2%)
Schwannoma Malignant 1 (2%)
Uterus (53) (54) (53) (53) (53) (50)
Carcinoma 1 (2%) 1 (2%) 1 (2%)
Leiomyosarcoma 3 (6%)
Polyp Stromal 6 (11%) 9 (17%) 4 (8%) 6 (11%) 3 (6%) 2 (4%)
Polyp Stromal, Multiple 1 (2%)
Schwannoma Malignant 1 (2%) 1 (2%)
Squamous Cell Carcinoma 2 (4%)
Cervix, Carcinoma 1 (2%)
Cervix, Schwannoma Malignant 1 (2%)
Cervix, Schwannoma Malignant, Metastatic,
Vagina 1 (2%)
Cervix, Squamous Cell Carcinoma 1 (2%)
Vagina (1) (3) (2) (1) (1) (3)
Fibrosarcoma 2 (67%)
Fibrous Histiocytoma, Metastatic, Skin 1 (100%)
Sarcoma 1 (33%)
Schwannoma Malignant 1 (100%) 3 (100%)
Squamous Cell Carcinoma 1 (50%) 1 (100%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (53) (54) (53) (53) (53) (51)
Histiocytic Sarcoma 1 (2%)
Lipoma 1 (2%)
Lymph Node (3) (3) (3) (2) (5) (6)
Deep Cervical, Carcinoma, Metastatic,
Thyroid Gland 1 (20%)
Mediastinal, Carcinoma, Metastatic, Uterus 1 (20%)
Mediastinal, Histiocytic Sarcoma 1 (50%)
Lymph Node, Mandibular (51) (52) (53) (51) (53) (51)
Lymph Node, Mesenteric (52) (54) (53) (53) (53) (51)
Carcinoma, Metastatic, Uterus 1 (2%)
Page 4
NTP Experiment-Test: 96021-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TOXIC EQUIVALENCY FACTOR EVALUATION (PCB 153) Date: 12/15/03
Route: GAVAGE Time: 11:03:02
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 UG/KG 10 UG/KG 100 300 1000 3000
UG/KG UG/KG UG/KG UG/KG
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Histiocytic Sarcoma 1 (2%)
Spleen (53) (54) (53) (53) (53) (51)
Histiocytic Sarcoma 1 (2%)
Thymus (48) (53) (52) (53) (53) (47)
Hemangiosarcoma, Metastatic, Heart 1 (2%)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (53) (54) (53) (53) (53) (51)
Adenoma 1 (2%) 1 (2%) 1 (2%) 3 (6%) 2 (4%)
Adenoma, Multiple 1 (2%)
Carcinoma 8 (15%) 6 (11%) 7 (13%) 4 (8%) 6 (11%) 2 (4%)
Carcinoma, Multiple 1 (2%)
Fibroadenoma 22 (42%) 21 (39%) 22 (42%) 22 (42%) 27 (51%) 24 (47%)
Fibroadenoma, Multiple 19 (36%) 13 (24%) 14 (26%) 13 (25%) 12 (23%) 8 (16%)
Skin (53) (54) (53) (53) (53) (51)
Basal Cell Adenoma 1 (2%)
Basal Cell Carcinoma 1 (2%) 1 (2%)
Fibroma 2 (4%) 1 (2%) 1 (2%)
Fibrosarcoma 1 (2%) 1 (2%)
Fibrous Histiocytoma 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%)
Keratoacanthoma 1 (2%) 1 (2%)
Lipoma 1 (2%)
Sarcoma 1 (2%)
Schwannoma Malignant 1 (2%)
Schwannoma Malignant, Metastatic, Vagina 1 (2%)
Squamous Cell Papilloma 1 (2%)
Subcutaneous Tissue, Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
None
____________________________________________________________________________________________________________________________________
Page 5
NTP Experiment-Test: 96021-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TOXIC EQUIVALENCY FACTOR EVALUATION (PCB 153) Date: 12/15/03
Route: GAVAGE Time: 11:03:02
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 UG/KG 10 UG/KG 100 300 1000 3000
UG/KG UG/KG UG/KG UG/KG
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (53) (54) (53) (53) (53) (51)
Astrocytoma Malignant 1 (2%)
Carcinoma, Metastatic, Pituitary Gland 1 (2%)
Carcinoma, Metastatic, Oral Mucosa 1 (2%)
Neurofibrosarcoma, Metastatic, Tooth 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (52) (54) (53) (53) (53) (51)
Alveolar/Bronchiolar Adenoma 1 (2%) 2 (4%)
Basal Cell Carcinoma, Metastatic, Skin 1 (2%)
Carcinoma, Metastatic, Mammary Gland 1 (2%) 1 (2%) 1 (2%)
Carcinoma, Metastatic, Uterus 1 (2%)
Carcinoma, Metastatic, Oral Mucosa 1 (2%)
Fibrous Histiocytoma, Metastatic, Skin 1 (2%)
Histiocytic Sarcoma 1 (2%)
Mediastinum, Hemangiosarcoma, Metastatic,
Heart 1 (2%)
Nose (53) (54) (53) (53) (53) (51)
Trachea (52) (54) (53) (53) (53) (51)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (53) (54) (53) (53) (52) (51)
Neurofibrosarcoma, Metastatic, Tooth 1 (2%)
Harderian Gland (53) (54) (53) (53) (53) (49)
Carcinoma, Metastatic, Oral Mucosa 1 (2%)
Neurofibrosarcoma, Metastatic, Tooth 1 (2%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (53) (54) (53) (53) (53) (51)
Carcinoma, Metastatic, Mammary Gland 1 (2%)
Histiocytic Sarcoma 1 (2%)
Nephroblastoma 1 (2%)
Stromal Nephroma 1 (2%) 1 (2%)
Bilateral, Renal Tubule, Carcinoma 1 (2%)
Renal Tubule, Adenoma 1 (2%)
Urinary Bladder (53) (53) (53) (53) (53) (50)
Page 6
NTP Experiment-Test: 96021-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TOXIC EQUIVALENCY FACTOR EVALUATION (PCB 153) Date: 12/15/03
Route: GAVAGE Time: 11:03:02
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 UG/KG 10 UG/KG 100 300 1000 3000
UG/KG UG/KG UG/KG UG/KG
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(53) *(54) *(53) *(53) *(53) *(51)
Histiocytic Sarcoma 1 (2%)
Leukemia Mononuclear 1 (2%)
Lymphoma Malignant 2 (4%) 3 (6%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 7
NTP Experiment-Test: 96021-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TOXIC EQUIVALENCY FACTOR EVALUATION (PCB 153) Date: 12/15/03
Route: GAVAGE Time: 11:03:02
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 0 UG/KG 10 UG/KG 100 300 1000 3000
UG/KG UG/KG UG/KG UG/KG
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 52 51 49 48 51 48
Total Primary Neoplasms 108 100 105 97 117 70
Total Animals with Benign Neoplasms 50 41 45 46 49 40
Total Benign Neoplasms 91 77 87 80 102 58
Total Animals with Malignant Neoplasms 12 20 16 14 14 11
Total Malignant Neoplasms 17 23 18 17 15 12
Total Animals with Metastatic Neoplasms 3 2 2 4 4
Total Metastatic Neoplasm 8 5 2 8 5
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 8
NTP Experiment-Test: 96021-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TOXIC EQUIVALENCY FACTOR EVALUATION (PCB 153) Date: 12/15/03
Route: GAVAGE Time: 11:03:02
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 3000 UG/
KG STOP
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50
Early Deaths
Natural Death 14
Moribund Sacrifice 16
Survivors
Terminal Sacrifice 20
Animals Examined Microscopically 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Small, Jejunum (49)
Fibrosarcoma 1 (2%)
Liver (50)
Cholangioma 1 (2%)
Cholangioma, Multiple 1 (2%)
Pancreas (50)
Acinus, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50)
Fibrous Histiocytoma, Metastatic, Skin 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Medulla (50)
Pheochromocytoma Benign 6 (12%)
Islets, Pancreatic (50)
Adenoma 1 (2%)
Carcinoma 1 (2%)
Parathyroid Gland (45)
Adenoma 1 (2%)
Pituitary Gland (50)
Pars Distalis, Adenoma 23 (46%)
Pars Distalis, Carcinoma 1 (2%)
Thyroid Gland (49)
C-Cell, Adenoma 18 (37%)
Page 9
NTP Experiment-Test: 96021-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TOXIC EQUIVALENCY FACTOR EVALUATION (PCB 153) Date: 12/15/03
Route: GAVAGE Time: 11:03:02
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 3000 UG/
KG STOP
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - cont
C-Cell, Carcinoma 3 (6%)
Follicular Cell, Adenoma 2 (4%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (49)
Cystadenoma 1 (2%)
Granulosa-Theca Tumor Benign 1 (2%)
Uterus (49)
Carcinoma 1 (2%)
Polyp Stromal 4 (8%)
Cervix, Schwannoma Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
None
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (50)
Carcinoma 10 (20%)
Fibroadenoma 16 (32%)
Fibroadenoma, Multiple 14 (28%)
Skin (50)
Basal Cell Carcinoma 1 (2%)
Fibroma 2 (4%)
Fibrosarcoma 4 (8%)
Fibrous Histiocytoma 1 (2%)
Schwannoma Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
Page 10
NTP Experiment-Test: 96021-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TOXIC EQUIVALENCY FACTOR EVALUATION (PCB 153) Date: 12/15/03
Route: GAVAGE Time: 11:03:02
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 3000 UG/
KG STOP
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50)
Schwannoma Malignant, Metastatic, Skin 1 (2%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50)
Carcinoma, Metastatic, Pituitary Gland 1 (2%)
Meninges, Sarcoma 1 (2%)
Meninges, Schwannoma Malignant, Metastatic,
Skin 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50)
Carcinoma, Metastatic, Mammary Gland 1 (2%)
Fibrous Histiocytoma, Metastatic, Skin 1 (2%)
Nose (50)
Basal Cell Carcinoma, Metastatic, Skin 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (50)
Optic Nerve, Schwannoma Malignant,
Metastatic, Skin 1 (2%)
Harderian Gland (50)
Schwannoma Malignant, Metastatic, Skin 1 (2%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50)
Fibrous Histiocytoma, Metastatic, Skin 1 (2%)
Stromal Nephroma 1 (2%)
Page 11
NTP Experiment-Test: 96021-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TOXIC EQUIVALENCY FACTOR EVALUATION (PCB 153) Date: 12/15/03
Route: GAVAGE Time: 11:03:02
____________________________________________________________________________________________________________________________________
SPRAGUE-DAWLEY RATS FEMALE 3000 UG/
KG STOP
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 49
Total Primary Neoplasms 119
Total Animals with Benign Neoplasms 44
Total Benign Neoplasms 92
Total Animals with Malignant Neoplasms 23
Total Malignant Neoplasms 27
Total Animals with Metastatic Neoplasms 5
Total Metastatic Neoplasm 10
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 12
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------